Veregen

(Sinecatechins)

Phase 2Small molecule

IIstituto Clinico Humanitas

Veregen is one of 38 small molecule programs targeting Prostate Carcinoma. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

FDA Application

NDA/BLA/ANDA regulatory filings

Patents

Pipeline

Status by Indication[3][1]

Indication

Prostate CarcinomaActive, not recruiting

Prostate CarcinomaPhase 2

Active, not recruiting

Competition

Competitive Landscape

39 competitors in Prostate Carcinoma

#DrugCompanyPhaseTrials

Erleada

Johnson & Johnson

Approved

2 2

Nubeqa

Bayer

Approved

1 3

Ritalin

Farxiga

Jevtana

Balversa

Estrace

Lynparza

Lupron

Sun Pharmaceutical Industries, Inc.

Xtandi

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

Phase 2Active, not recruiting

Prostate Carcinoma

NCT04597359

Clinical

Trials by Indication[1]

Prostate Carcinoma1 trial

A Phase II Randomized Double Blinded Study of Green Tea Catechins (GTC) vs. Placebo in Men on Active Surveillance for Prostate Cancer: Modulation of Biological and Clinical Intermediate Biomarkers

Active, not recruiting·EECOG-ACRIN Cancer Research Group·Phase 2·NCT04597359·360 enrolled

Regulatory

FDA Approval Timeline[4]

Oct 31, 2006

VEREGEN

NDA NDA021902

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Sinecatechins. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Sinecatechins compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Sinecatechins. EMBL-EBI & Wellcome Sanger Institute.
[4]
OpenFDA — FDA approval records (NDA NDA021902). U.S. Food & Drug Administration.
[5]
FDA Orange Book — Patent and exclusivity data for Veregen. U.S. Food & Drug Administration.
[6]
SEC EDGAR — Istituto Clinico Humanitas company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: IIstituto Clinico Humanitas

Patent Landscape[5]

Patent Cliff

Oct 2, 2026

Earliest patent expiration — generic entry possible after this date

Patent #Expires

7858662Oct 2, 2026

Veregen

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2027

Trials by Indication[1]

Prostate Carcinoma1 trial

FDA Approval Timeline[4]

References

Drug Info

Quick Facts

Patent Landscape[5]

Related News